Vector in Medical Technology
Navigation Links
Vector in Medical Technology
... license to utilize Adeno-Associated Viral (AAV) vector technology in heart failure, which bodes well for ... is a recombinant adeno-associated viral (rAAV) vector that transfers the SERCA2a gene into heart muscle ... low levels of pre-existing antibodies to the AAV vector did not show improvement in these parameters. The ...
... represented by the first and so far only targeted vector that has been tested in the clinic: the ... acclaimed and heavily subsidized National Gene vector Laboratories (NGVL) -- whose mission and "primary goal" as an academic vector production facility and national resource was ...
... tests showed there was no replication of vector and only trace amounts of vector DNA in tissues outside the joint. Consequently, ... and clinical findings that indicate the level of vector that is present outside the locally treated area ...
... the performance of, or potentially even eliminate the need for, the viral vector vaccine boost. The SMI is sponsoring the development. About the Vaccine ... was developed by the SMI and the Karolinska Institute in Sweden. The viral vector boost vaccine component uses a Modified Vaccinia Ankara (MVA) virus (the ...
... against his/her own cancer can be achieved by combining (1) the targeted vector bearing a potent cytocidal construct, Rexin-G, with (2) a targeted vector bearing an immune activating gene, Reximmune-C. Rexin-G is given first to ...
... Phase II clinical trial, has yielded valuable insights for the entire gene therapy field, dispelling many myths and revealing strategies to enhance vector uptake in humans with numerous applications." While conventional drug therapies have improved survival of patients with congestive heart ...
... and based in Plymouth, Minnesota. Major investors in Atritech include SplitRock Partners, Prism Venture Partners, Tullis-Dickerson Partners, , The vector Group, Thoma Cressey Funds, SightLine Funds and Affinity Capital. For more information, visit http://www.atritech.net . ...
... technology. (Logo: http://www.newscom.com/cgi-bin/prnh/20081205/DC50112LOGO ) Joseph L. Bruder, Ph.D., GenVec's Director of vector and Vaccine Programs, will give two research presentations: "Advanced generation adeno-based vectors for malaria vaccine development" and ...
... and left ventricular function/remodeling (6 patients). Of the nine patients treated, two with low levels of pre-existing antibodies to the AAV vector did not show improvement in these parameters. The data are consistent with safety established for other rAAV vectors, which has been demonstrated ...
... is intended to optimize the priming of immune responses and increase the performance of, or potentially even eliminate the need for, the viral vector vaccine boost. The SMI is sponsoring the development. About the Vaccine The SMI/KI vaccines contain synthetic versions of genes encoding internal ...
... of Rexin-G for metastatic bone and soft tissue sarcoma (J Clin Oncol 26: 14509, 2008). Rexin-G is the first and so far only targeted gene therapy vector that has been tested in the clinic (Nature Reviews/Genetics 2007). In this open label study, cohorts of 6 to 7 patients with all types of sarcoma, ...
... with innovations ranging from oncogene discovery, to designer therapeutic genes, to pathotropic (disease-seeking) targeting, to high-performance vector engineering, advanced biopharmaceutical manufacturing and bioprocess development, Epeius Biotechnologies is well positioned to "launch" its enabling ...
... portfolio around its proprietary RNAi Nanoplex (NPX) delivery technology. The RNAi NPX delivery technology is a modular, multi-component delivery vector that carries active siRNA molecules in its core with the flexibility to attach a Polyethylene Glycol (PEG) layer and/or a targeting ligand to the ...
... immobilized form of local gene delivery that allows for control of gene dispersion. GAM consists of a biocompatible matrix comprising a gene or DNA vector encoding a growth factor or other therapeutic protein. For tissue repair, the application method involves placement of a GAM gel directly onto a ...
... with innovations ranging from gene discovery, to designer therapeutic genes, to pathotropic (disease-seeking) targeting, to ultra high-performance vector engineering, to advanced biopharmaceutical manufacturing and bioprocess development, Epeius Biotechnologies is well positioned to 'launch' its ...
... RNAi Nanoplex(TM) technology, a powerful combination of advanced delivery systems. The RNAi Nanoplex(TM) technology is a multi-component delivery vector that carries active siRNA molecules in its core and in its targeted form (TargeTran(TM)) carries a ligand attached to its surface for specific tissue ...
... VNP40541, a hypoxia-selective compound, and hydrazone compounds. The Company is seeking development partners for TAPET(R), its modified Salmonella vector used to deliver anticancer agents directly to tumors. For additional information on Vion and its product development programs, visit the Company's ...
... Vaccine Evaluation (PAVE). The PAVE trial will test a vaccine regimen combining a DNA prime based on Vical's technology with an adenoviral vector boost in up to 8,500 volunteers at sites in the United States, Africa, the Caribbean and South America to determine its potential to prevent ...
... a hypoxia-selective compound, and hydrazone compounds. The Company also is seeking development partners for TAPET(R), its modified Salmonella vector used to deliver anticancer agents directly to tumors. For additional information on Vion and its product development programs, visit the Company's ...
... Oncology. The researchers call the system a versatile expression vector - nicknamed VISA. It includes a targeting agent, also called a promoter, ... normal pancreatic, lung and breast cells. The next step was to load the vector with a weapon. The team packaged its mutant version of the Bik gene along ...
... a hypoxia-selective compound, and hydrazone compounds. The Company also is seeking development partners for TAPET(R), its modified Salmonella vector used to deliver anticancer agents directly to tumors. For additional information on Vion and its product development programs, visit the Company's ...
AlphaVax Announces Promising Results in Melanoma Studies
... the ability of AlphaVax's virus-like replicon vector particles (VRP) encoding melanoma-specific tumor ... intervention with a novel vaccine vector such as ours may prove beneficial as a treatment ... company that uses a novel alphavirus vector platform technology that has proven to be highly ...VIRxSYS to Host a Web Conference to Announce Clinical Trial Update
... removed. VIRxSYS used this vector to deliver RNA antisense targeting the HIV ... a new vaccine approach that uses a lentiviral vector expressing HIV antigens. In the study, VRX1023 ... gene therapies because it uses a lentiviral vector derived from HIV-1 itself. Unlike other viral ...Gene Therapy Improves Vision in Patients with Congenital Retinal Disease
... better functioning eye. The LCA gene therapy vector showed no signs of causing inflammation in the ... biological effects of the therapeutic gene or the vector used to carry it. The patients enrolled in ... a period of six months following the gene therapy vector administration. One patient was better able to ...In Blood Vessel Stents, Innovative Materials Allow Better Control, Delivery of Gene Therapy
... is an amplifier that increases the dose of gene vector more than fourfold over the previous ... component, the stent can be tuned to release vector at a controlled rate that can theoretically be ... studies have shown that 90 percent of the gene vector is released within 12 to 24 hours, after which ...VIRxSYS Presents Data on HIV Vaccine at Keystone HIV Vaccine Symposia
... HIV-Based Lentiviral vector VRX1023 Shows Promising Results GAITHERSBURG, ... approach -- using HIV-based lentivector as vector boost. VRX1023, an HIV antigen expressing ... is using an engineered HIV-based lentiviral vector to deliver the vaccinating antigens. In small ...... represented by the first and so far only targeted vector that has been tested in the clinic: the ... acclaimed and heavily subsidized National Gene vector Laboratories (NGVL) -- whose mission and "primary goal" as an academic vector production facility and national resource was ...
AlphaVax Announces Results From Phase 1 Influenza Vaccine Clinical Trial
... to further assess the properties of this unique vector system as well as the feasibility of its ... infected individuals. Using essentially the same vector technology, AlphaVax is currently also conducting ... company that uses a novel alphavirus vector platform technology that has proven to be highly ...... tests showed there was no replication of vector and only trace amounts of vector DNA in tissues outside the joint. Consequently, ... and clinical findings that indicate the level of vector that is present outside the locally treated area ...
Multiple NIH Phase 2 HIV Vaccine Trials Using Vical's Technology Produce Encouraging Results
... Phase 1 conclusions that a "DNA prime-adenoviral vector boost" vaccine regimen was safe and ... uses a replication-defective adenoviral vector to shuttle the same non-infectious gene sequences ... and was manufactured by Vical. The adenoviral vector vaccine was developed by VRC in collaboration ...... the performance of, or potentially even eliminate the need for, the viral vector vaccine boost. The SMI is sponsoring the development. About the Vaccine ... was developed by the SMI and the Karolinska Institute in Sweden. The viral vector boost vaccine component uses a Modified Vaccinia Ankara (MVA) virus (the ...
AlphaVax Continues to Expand the Use of Its Vaccine Platform
... to date is an excellent demonstration of the potential of our alphavirus vector platform to address many different diseases as well as bioterrorism ... North Carolina-based, clinical-stage company that uses a novel alphavirus vector platform technology that has proven to be highly flexible and immunogenic, ...... against his/her own cancer can be achieved by combining (1) the targeted vector bearing a potent cytocidal construct, Rexin-G, with (2) a targeted vector bearing an immune activating gene, Reximmune-C. Rexin-G is given first to ...
AlphaVax Announces Initial Analysis of Data From CMV Phase 1 Clinical Trial
... (CMV) vaccine that is based on its platform alphavirus replicon vector technology. The trial is a placebo-controlled, randomized, double-blind, ... North Carolina-based, clinical-stage company that uses a novel alphavirus vector platform technology that has proven to be highly flexible and immunogenic, ...Ceregene Presents Long-term Follow-up From Phase 1 Trial of CERE-120 in Parkinson's Disease
... About CERE-120 CERE-120 is composed of an adeno-associated virus (AAV) vector carrying the gene for neurturin (NTN), a naturally occurring protein known ... delivery. Ceregene's clinical programs include CERE-110, an AAV2 based vector expressing nerve growth factor that is currently in Phase 1/2 studies for ...Researchers Create First Targeted Knockout Rats Using Zinc Finger Nuclease Technology
... in organ transplantation. The rat is an important immunological model, and INSERM routinely generates transgenic rats using DNA or lentiviral vector microinjection. The generation of transgenic rats also is open to the scientific community through an open facility. More information is available ...AlphaVax Announces Results from Initial Testing of Its H1N1 (Swine) Influenza Vaccine
... Abo u t Alph a Vax AlphaVax, Inc. is a North Carolina-based, clinical-stage company that uses a proprietary alphavirus vector platform technology that has proven to be highly flexible and immunogenic, and allows the same manufacturing, formulation, and delivery strategies to ...... Phase II clinical trial, has yielded valuable insights for the entire gene therapy field, dispelling many myths and revealing strategies to enhance vector uptake in humans with numerous applications." While conventional drug therapies have improved survival of patients with congestive heart ...
NewCardio Leadership to Present Two Abstracts at ISCE Conference
... to unexpected distortions in key parameters that affect drug safety assessment. "End of T Wave Determination by Polynomial Curve Fitting on a vector Magnitude Lead," authored by Drs. Bosko Bojovic, Ljupco Hadzievski, Ihor Gussak, Samuel George and Branislav Vajdic. This presentation will feature ...... and based in Plymouth, Minnesota. Major investors in Atritech include SplitRock Partners, Prism Venture Partners, Tullis-Dickerson Partners, , The vector Group, Thoma Cressey Funds, SightLine Funds and Affinity Capital. For more information, visit http://www.atritech.net . ...
... technology. (Logo: http://www.newscom.com/cgi-bin/prnh/20081205/DC50112LOGO ) Joseph L. Bruder, Ph.D., GenVec's Director of vector and Vaccine Programs, will give two research presentations: "Advanced generation adeno-based vectors for malaria vaccine development" and ...
... and left ventricular function/remodeling (6 patients). Of the nine patients treated, two with low levels of pre-existing antibodies to the AAV vector did not show improvement in these parameters. The data are consistent with safety established for other rAAV vectors, which has been demonstrated ...
Encouraging Gene Therapy Results in Genetic Form of Blindness
... for 90 days to assess changes in the eye and in their vision compared to the untreated eye. The replacement RPE65 gene was packaged in a gene therapy vector engineered from a recombinant adeno-associated virus. All of the patients self-reported improved vision under dim light conditions, and the authors ...... is intended to optimize the priming of immune responses and increase the performance of, or potentially even eliminate the need for, the viral vector vaccine boost. The SMI is sponsoring the development. About the Vaccine The SMI/KI vaccines contain synthetic versions of genes encoding internal ...
... of Rexin-G for metastatic bone and soft tissue sarcoma (J Clin Oncol 26: 14509, 2008). Rexin-G is the first and so far only targeted gene therapy vector that has been tested in the clinic (Nature Reviews/Genetics 2007). In this open label study, cohorts of 6 to 7 patients with all types of sarcoma, ...
... with innovations ranging from oncogene discovery, to designer therapeutic genes, to pathotropic (disease-seeking) targeting, to high-performance vector engineering, advanced biopharmaceutical manufacturing and bioprocess development, Epeius Biotechnologies is well positioned to "launch" its enabling ...
... portfolio around its proprietary RNAi Nanoplex (NPX) delivery technology. The RNAi NPX delivery technology is a modular, multi-component delivery vector that carries active siRNA molecules in its core with the flexibility to attach a Polyethylene Glycol (PEG) layer and/or a targeting ligand to the ...
... immobilized form of local gene delivery that allows for control of gene dispersion. GAM consists of a biocompatible matrix comprising a gene or DNA vector encoding a growth factor or other therapeutic protein. For tissue repair, the application method involves placement of a GAM gel directly onto a ...
... with innovations ranging from gene discovery, to designer therapeutic genes, to pathotropic (disease-seeking) targeting, to ultra high-performance vector engineering, to advanced biopharmaceutical manufacturing and bioprocess development, Epeius Biotechnologies is well positioned to 'launch' its ...
... RNAi Nanoplex(TM) technology, a powerful combination of advanced delivery systems. The RNAi Nanoplex(TM) technology is a multi-component delivery vector that carries active siRNA molecules in its core and in its targeted form (TargeTran(TM)) carries a ligand attached to its surface for specific tissue ...
The Oral Cancer Foundation Urges HPV Vaccination for Males
... begin to see the positive collateral benefits in the oral and head and neck cancer world. Hill says. Vaccinating males will also eliminate them as a vector for the virus. On the other hand, the foundation cautions that while Pharma giants Merck and GlaxoSmithKline are doing studies on the current ...Thermo Fisher Scientific Advances Gene-Silencing Technology for Life Sciences Research
... causing high levels of unintended gene silencing that can lead to flawed experimental results." By combining shRNA with Lentigen's proprietary viral vector delivery system, the gene silencing sequence is integrated into the host cell genome. This creates permanent gene silencing that cannot be achieved ...... VNP40541, a hypoxia-selective compound, and hydrazone compounds. The Company is seeking development partners for TAPET(R), its modified Salmonella vector used to deliver anticancer agents directly to tumors. For additional information on Vion and its product development programs, visit the Company's ...
Atritech Announces Completion of a $22 Million Equity Financing
... held and based in Plymouth, Minnesota. Major investors in Atritech include SplitRock Partners, Prism Venture Partners, Tullis-Dickerson Partners, The vector Group, Thoma Cressey Funds, SightLine Funds and Affinity Capital. For more information, visit http://www.atritech.net . About SightLine Partners ...... Vaccine Evaluation (PAVE). The PAVE trial will test a vaccine regimen combining a DNA prime based on Vical's technology with an adenoviral vector boost in up to 8,500 volunteers at sites in the United States, Africa, the Caribbean and South America to determine its potential to prevent ...
... a hypoxia-selective compound, and hydrazone compounds. The Company also is seeking development partners for TAPET(R), its modified Salmonella vector used to deliver anticancer agents directly to tumors. For additional information on Vion and its product development programs, visit the Company's ...
Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the Treatment of Alzheimer's Disease
... loss in this disease". About CERE-110 CERE-110 is composed of an AAV vector carrying the gene for NGF, a naturally occurring protein that maintains ... blockade of this system may restore memory. Delivery of NGF using an AAV vector may have the potential to induce sustained expression of NGF, resulting in ...... Oncology. The researchers call the system a versatile expression vector - nicknamed VISA. It includes a targeting agent, also called a promoter, ... normal pancreatic, lung and breast cells. The next step was to load the vector with a weapon. The team packaged its mutant version of the Bik gene along ...
... a hypoxia-selective compound, and hydrazone compounds. The Company also is seeking development partners for TAPET(R), its modified Salmonella vector used to deliver anticancer agents directly to tumors. For additional information on Vion and its product development programs, visit the Company's ...
Other ContentsparaffinparaffinparaffinsinusessinusesparanasalparanoiaparanoiaparanoiaparentingparentingadenomaadenomaadenomaOther TagsIFNBINDERSartoriusGRIPGRIPGRIPOther Tagsinstituted 2instituted 3instituted 4modeling 2modeling 3smoked 2smoked 3smoked 4smoked 5smoked 6smoked 7smoked 8smoked 9smoked 10answers 2answers 3seek 2seek 3seek 4seek 5seek 6potential 2potential 3potential 4potential 5potential 6potential 7potential 8potential 9potential 10version 2version 3version 4version 5version 6version 7version 8version 9version 10gold 2gold 3gold 4
(Date:11/23/2009)... CINCINNATINew research presents strong evidence t...e to both outdoor traffic-related pollution and in...s than one or the other exposure alone. , Envi...incinnati (UC) College of Medicine have shown that...elated particles and indoor endotoxin during early...
(Date:11/23/2009)..., TORONTO, November 23, 2009 - The time of day ma...ing to a new paper produced by a research team led...nto Scarborough,s vice-principal for research and ...iology at the St. George campus. , Capitalizin...he poplar tree, the research team examined how pop...
(Date:11/23/2009)... Farmington, CT Current research suggests that a ...sease. The related report by Nichols et al, "Uniq...a New Class of TLR2 Ligands Capable of Enhancing A...f The American Journal of Pathology . , Multipl...m attacks the brain and spinal cord, affects nearl...
Breaking Biology News(10 mins):Exposure to both traffic, indoor pollutants puts some kids at higher risk for asthma later 2Time of day matters to thirsty trees, U of T researcher discovers 2Factors from common human bacteria may trigger multiple sclerosis 2FDA Approves NovoLog 28R 29 Labeling Update 51814 1FDA Approves NovoLog 28R 29 Labeling Update 51814 2FDA Approves NovoLog 28R 29 Labeling Update 51814 3FDA Approves NovoLog 28R 29 Labeling Update 51814 4Fraternal Order of Eagles Award 24630 000 in Grants at International Convention 51809 1Fraternal Order of Eagles Award 24630 000 in Grants at International Convention 51809 2Tube Feeding Error 3A Fatal Medical Mistakes 51804 1Tube Feeding Error 3A Fatal Medical Mistakes 51804 2Tube Feeding Error 3A Fatal Medical Mistakes 51804 3(Date:11/25/2009)... vaccine carried into the body on a carefully engi...uccessfully eliminate tumors in mammals, scientist...tional Medicine . , The new approach, pioneered ...rsity, uses plastic disks impregnated with tumor-s...eprogram the mammalian immune system to attack tum...
(Date:11/25/2009)...s that can occur in children with autism and relat... that includes medication combined with a structur... University researchers and their colleagues. , ...nal of the American Academy of Child and Adolescen...onal Institute of Mental Health (NIMH) Research Un...
(Date:11/25/2009)...esh that mimicked parts of speech colored percepti...lthDay News) -- People can "hear" not only with th...hows. , In fact, sensations on the skin designe... people decipher sounds better, the Canadian scien... whether we could use tactile information in this ...
(Date:11/25/2009)...iative expands to include cost-effective, sustaina...healthcare professionals in developing world. , ...mber 25, 2009 -- Elluminate, Inc. , the leader in...s that support 21st century teaching, learning, a...nd Ice initiative was awarded iNACOL,s first-eve...
(Date:11/25/2009)...wswire-FirstCall/--TheAdvisoryBoardCompany(Nasdaq:...tAnnualPiperJaffrayHealthCareConferenceinNewYorkCi...M(EST),willbetheCompany,sChiefExecutiveOfficer,Rob...cer,MichaelT.Kirshbaum.Thepresentationmaterialswil...ww.advisoryboardcompany.com ,throughDecember16,200...
Breaking Medicine News(10 mins):Health News:Implant-based cancer vaccine is first to eliminate tumors in mice 2Health News:Parent training key to improved treatment of behavior problems in children with autism 2Health News:Your Skin Can Help Your Ears Listen 2Health News:Your Skin Can Help Your Ears Listen 3Health News:Elluminate's Fire and Ice Project Recognized as First-Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 2Health News:Elluminate's Fire and Ice Project Recognized as First-Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 3Health News:Elluminate's Fire and Ice Project Recognized as First-Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 4Health News:Elluminate's Fire and Ice Project Recognized as First-Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 5[1] Implant-based cancer vaccine is first to eliminate tumors in mice[0] Parent training key to improved treatment of behavior problems in children with autism[0] Your Skin Can Help Your Ears Listen [1] Elluminate's Fire and Ice Project Recognized as First-Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice[0] The Advisory Board Company to Present at 21st Annual Piper Jaffray Health Care Conference
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |